Compare ASR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASR | CYTK |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | Mexico | United States |
| Employees | 1882 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.6B |
| IPO Year | N/A | 2004 |
| Metric | ASR | CYTK |
|---|---|---|
| Price | $295.72 | $76.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $365.00 | $89.26 |
| AVG Volume (30 Days) | 59.0K | ★ 2.9M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 12.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $7.44 | $7.37 |
| Revenue Next Year | $9.69 | $310.19 |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $292.35 | $29.81 |
| 52 Week High | $381.52 | $80.20 |
| Indicator | ASR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 62.85 |
| Support Level | N/A | $58.59 |
| Resistance Level | $318.64 | $80.20 |
| Average True Range (ATR) | 6.82 | 3.82 |
| MACD | -0.18 | 0.90 |
| Stochastic Oscillator | 11.18 | 81.88 |
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.